Volume 31, No 10, Oct 2021

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 31 Issue 10, October 2021: 1126-1129   |  Open Access

LETTERS TO THE EDITOR

Structure-based analyses of neutralization antibodies interacting with naturally occurring SARS-CoV-2 RBD variants

Hua Xu^1,† , Bo Wang^1,† , Tian-Ning Zhao^1,† , Zi-Teng Liang^2,† , Tian-Bo Peng¹ , Xiao-Hui Song¹ , Jia-Jing Wu² , You-Chun Wang^2,* , Xiao-Dong Su^1,*

¹State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, and Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, China
²Division of HIV/AIDS and Sextransmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China
^†These authors contributed equally: Hua Xu, Bo Wang, Tian-Ning Zhao, Zi-Teng Liang
Correspondence: You-Chun Wang(wangyc@nifdc.org.cn)Xiao-Dong Su(xdsu@pku.edu.cn)

Dear Editor,

SARS-CoV-2 variants are developing rapidly among COVID-19 patients, likely resulting in higher transmissibility at the population level.1,2,3,4,5 Mutations in the spike proteins (S proteins) of these variants are supposed to be related with receptor binding and virus invasion. Examples of these prevalent variants include the B.1.1.7 lineage that emerged in the United Kingdom (UK), the B.1.351 lineage (also termed 501Y.V2) in South Africa (SA), and the P.1 and P.2 lineages in Brazil, etc. Many S protein alterations, especially in the receptor binding domain (RBD), characterize these variants, e.g., the N501Y mutation in B.1.351 and the K417N (or T)/E484K/N501Y co-mutation in the SA and Brazil variant.2,3,5 The RBD is responsible for interacting with mammalian receptor angiotensin-converting enzyme 2 (ACE2) to mediate the viral infection of host cells. It is also concentrated with epitopes for neutralizing antibodies (NAbs), thus playing a vital role in the study of prophylactics and therapeutics for COVID-19.6,7,8,9,10 Whether those RBD mutations may alter virus–host cell interactions and gain resistance to NAbs needs to be addressed.

https://doi.org/10.1038/s41422-021-00554-1

FULL TEXT | PDF

Browse 739